Welcome to our dedicated page for Vicore Pharma Hldg AB news (Ticker: VCRE), a resource for investors and traders seeking the latest updates and insights on Vicore Pharma Hldg AB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vicore Pharma Hldg AB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vicore Pharma Hldg AB's position in the market.
Vicore Pharma (NASDAQ:VCRE), a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists (ATRAGs), will participate in the Leerink Therapeutics Forum.
The event will be held on Tuesday, July 14, 2026, at the Boston Harbor Hotel in Boston, Massachusetts, and will feature 1×1 investor meetings with CEO Ahmed Mousa.
Vicore Pharma (Nasdaq US:VCRE) will begin trading American Depositary Shares (ADSs) on the Nasdaq Capital Market on July 2, 2026. Each ADS represents 10 common shares.
The Nasdaq US listing is a secondary listing, adds no new shares, and aims to expand access to US capital markets.